131 related articles for article (PubMed ID: 24268019)
41. Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department.
Wilsey BL; Fishman SM; Tsodikov A; Ogden C; Symreng I; Ernst A
Pain Med; 2008 Nov; 9(8):1107-17. PubMed ID: 18266809
[TBL] [Abstract][Full Text] [Related]
42. Comparative effectiveness in pain-related outcomes and health care utilizations between veterans with major depressive disorder treated with duloxetine and other antidepressants: a retrospective propensity score-matched comparison.
Shi L; Liu J; Zhao Y
Pain Pract; 2012 Jun; 12(5):374-81. PubMed ID: 21951787
[TBL] [Abstract][Full Text] [Related]
43. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients.
Tkacz J; Volpicelli J; Un H; Ruetsch C
J Subst Abuse Treat; 2014 Apr; 46(4):456-62. PubMed ID: 24332511
[TBL] [Abstract][Full Text] [Related]
44. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine.
Zhao Y; Chen SY; Wu N; Fraser KA; Boulanger L
Pain Pract; 2011; 11(4):381-91. PubMed ID: 21199311
[TBL] [Abstract][Full Text] [Related]
45. The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain.
Ivanova JI; Birnbaum HG; Yushkina Y; Sorg RA; Reed J; Merchant S
J Opioid Manag; 2013; 9(4):239-54. PubMed ID: 24353017
[TBL] [Abstract][Full Text] [Related]
46. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study.
Chang HY; Kharrazi H; Bodycombe D; Weiner JP; Alexander GC
BMC Med; 2018 May; 16(1):69. PubMed ID: 29764482
[TBL] [Abstract][Full Text] [Related]
47. Health care resource use and costs in opioid-treated patients with and without constipation in Brazil.
Takemoto ML; Fernandes RA; Almeida GR; Monteiro RD; Colombini-Neto M; Bertola-Neto A
Value Health; 2011; 14(5 Suppl 1):S78-81. PubMed ID: 21839904
[TBL] [Abstract][Full Text] [Related]
48. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
49. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
[TBL] [Abstract][Full Text] [Related]
50. Household members of persons with Alzheimer's disease: health conditions, healthcare resource use, and healthcare costs.
Suehs BT; Shah SN; Davis CD; Alvir J; Faison WE; Patel NC; van Amerongen D; Bobula J
J Am Geriatr Soc; 2014 Mar; 62(3):435-41. PubMed ID: 24576203
[TBL] [Abstract][Full Text] [Related]
51. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
Cicero TJ; Inciardi JA; Muñoz A
J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
[TBL] [Abstract][Full Text] [Related]
52. The burden of the nonmedical use of prescription opioid analgesics.
Gilson AM; Kreis PG
Pain Med; 2009 Jul; 10 Suppl 2():S89-100. PubMed ID: 19691688
[TBL] [Abstract][Full Text] [Related]
53. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
54. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia.
White LA; Robinson RL; Yu AP; Kaltenboeck A; Samuels S; Mallett D; Birnbaum HG
J Pain; 2009 Sep; 10(9):976-83. PubMed ID: 19556168
[TBL] [Abstract][Full Text] [Related]
55. Growth of intensive care unit resource use and its estimated cost in Medicare.
Milbrandt EB; Kersten A; Rahim MT; Dremsizov TT; Clermont G; Cooper LM; Angus DC; Linde-Zwirble WT
Crit Care Med; 2008 Sep; 36(9):2504-10. PubMed ID: 18679127
[TBL] [Abstract][Full Text] [Related]
56. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
57. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
[TBL] [Abstract][Full Text] [Related]
58. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
59. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease.
Kaltenboeck A; Johnson SJ; Davis MR; Birnbaum HG; Carroll CA; Tarrants ML; Siderowf AD
Parkinsonism Relat Disord; 2012 May; 18(4):321-6. PubMed ID: 22177623
[TBL] [Abstract][Full Text] [Related]
60. Economic Burden of Prescription Opioid Misuse and Abuse: A Systematic Review.
Oderda GM; Lake J; Rüdell K; Roland CL; Masters ET
J Pain Palliat Care Pharmacother; 2015; 29(4):388-400. PubMed ID: 26654413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
